Successfully reported this slideshow.
Your SlideShare is downloading. ×

Torch s in pregnancy

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Upcoming SlideShare
Torch infection in pregnancy
Torch infection in pregnancy
Loading in …3
×

Check these out next

1 of 65 Ad

More Related Content

Slideshows for you (20)

Advertisement

Similar to Torch s in pregnancy (20)

Recently uploaded (20)

Advertisement

Torch s in pregnancy

  1. 1. TORCH-S IN PREGNANCY Presenter Dr B.Msumi Facilitator Sr Dr Happy(MD,MMED)
  2. 2. Overview • TORCH COMPLEX is a medical acronym which stands for toxoplasmosis,other,rubella virus,cytomegalovirus infection and herpes simplex virus infection • The TORCH infections can lead to severe fetal anomalies or even fetal loss • They are a group of viral,bacterial and protozoan infections that gain access to the fetal bloodstream transplacentally via the chorionic villi
  3. 3. • Hematogenous transmission may occur at any time during gestation or occasionally at the time of delivery via maternal to fetal transfusion • The gestational age of fetus influenced the degree of severity • Treatment of maternal infection frequently has no impact on fetal outcome • They have mild maternal morbidity but serious fetal consequences
  4. 4. Toxoplasmosis • Is the disease caused by intracellular parasite toxoplasma gondii • a ubiquitous protozoan parasite that infects humans in various settings • mainly acquired during childhood and adolescence • Much higher rates of infection (up to 80 percent) are found in the tropics in communities exposed to contaminated soil, undercooked meat, or unfiltered water
  5. 5. Prevalence • Seroprevalence rates of toxoplasmosis vary substantially among different countries • Approximately 15 percent in the United States to more than 50 percent in certain European countries • In Tanzania only three studies have reported seroprevalence of T.gondii infection among pregnant women • Two of them are recently conducted in mwanza and KCMC with reported seroprevalence of 30.9% and 41.7% respectively • An older study in Dar es salaam reported seroprevalence of 35%
  6. 6. Vertical transmission • Congenital infection occurs via tachyzoites placental transmission after primary maternal infection during pregnancy • The risk of fetal transmission varies depending upon the GA during which maternal infection occurs • Transmission of toxoplasma to the foetus typically occurs after the placenta has become infected • Determinant of transmission is the development of placental blood flow which explains the increased rate of transmission later in pregnancy
  7. 7. Clinical features • Acute infection in adult humans goes unrecognized in as many as 90% of cases • The most common manifestations are nontender lymphadenopathy, fatigue, headache, malaise and myalgia • First trimester fetal infection on the other hand, often results in miscarriage, stillbirth, or severe sequelae in the newborn
  8. 8. Diagnosis Maternal infection • Serologic tests represent the most commonly used method to establish the diagnosis • Documentation of recent seroconversion is the best evidence of recent infection • IgG antibodies appear within one to two weeks of infection, peak in six to eight weeks and then decline over the next two years; they remain detectable for life
  9. 9. • IgM antibodies may appear within the first week of infection and generally decline within a few months • Sometimes persist for years after the initial infection • Thus, the presence of IgM antibodies should not be used to confirm a recent or acute infection.
  10. 10. Interpretation of results of serological tests for toxoplasmosis performed at clinical (nonreference) laboratories IgG test resu lt IgM test result Clinical relevance Neg Neg Interpreted to indicate that the women has not been infected with T.gondii,serial testing during pregnancy is advised.if such woman acquire primary infection during gestation ,they are at risk of transmitting infection to fetus Pos Neg During 1st or 2nd trimester most often reflects an infection acquired before the present pregnancy Neg Pos or equivocal IgM antibodies are detected early in the acute infection,because they may persist for prolonged period.IgM antibodies may be detected in pregnant women who were infected in the distant past and before gestation,hence +ve IgM result should be followed by confirmatory test at toxo reference lab Pos Pos or equivocal Same as above
  11. 11. Fetal infection • Prenatal diagnosis of congenital toxoplasmosis is made by detection of the Toxoplasma gondii parasite in fetal blood or amniotic fluid or presence of Toxoplasma gondii IgM or IgA antibodies in fetal blood • (PCR) testing is the preferred diagnostic modality
  12. 12. • Certain abnormalities on antenatal sonography are suggestive, but not diagnostic, of fetal infection. • They include intracranial densities, increased placental thickness and/or hyperdensity, ventricular dilatation, intrahepatic densities, hepatomegaly, ascites, pericardial and/or pleural effusion.
  13. 13. Newborn infection diagnosis • history and physical examination • Ophthalmologic, auditory, and neurologic examinations • lumbar puncture and (CT) of the head • Serum from the newborn can also be tested for IgM and IgA antibodies
  14. 14. • IgM measurement appears to be more sensitive when conducted with ELISA and ISAGA than IFA • IgA antibody measurment may be more sensitive than IgM, but specificity is not assured • Most experts recommend a combination of serologic tests.
  15. 15. Treatment • Spiramycin(1g 8hrly ) should be given until term • Once fetal infection is established,pyrimethamine 25mg bd orally and sulphadiazine 1g 8hrly orally for 3/52 alternating with 3/52 course of spiramycin 1g 8hrly until delivery
  16. 16. • Pyrimethamine 25mg od orally and sulphadiazine 4g/day administered continously until term • Leucovorin calcium 10-25mg/day orally is added during pyrimethane and sulphadiazine • Weekly monitoring of CBC and platelets counts • Treatment discontinued if significant abnormal results reported
  17. 17. Prevention • Women should avoid drinking unfiltered water in any setting • Avoid ingesting soil by observing strict hand hygiene after touching soil • Fruits and vegetables should be washed before eating • Women should avoid tasting meat while cooking
  18. 18. Syphilis • Definition • Syphilis is a systemic human disease caused by Treponema pallidum Classification Acquired (usually by sexual contact or through blood transfusion).  Early (includes: primary, secondary and early latent syphilis).  Late (includes: latent and tertiary gummatous, cardiovascular and neurosyphilis). Congenital (transmitted from mother to child in utero).  Early (first 2 years).  Late, including stigmata of congenital syphilis
  19. 19. Syphilis has three clinical stages • The primary stage:the infected person develops painless ulcer called chancre(starts 21 days(range 10-90days)following infection,last 2-6 weeks) WHO 2007 • The secondary stage:characterized by skin rash over the whole body,often with fever and muscle pain(starts 2-3 month after onset of chancre, last 2-6 weeks)followed by latent phase of many years with no sign or symptoms(WHO 2007)
  20. 20. • Latent syphilis-is the period after infection during which patients are seropositive but have no clinical manifestation of the disease • Early latent is when infection was acquired within preceding year • Late latent syphilis include all other cases(PAHO 2008)
  21. 21. Syphilis in pregnancy • Manifestation of syphilis in pregnancy are the same as for non-pregnant women • Syphilis may be acquired at any stage of pregnancy whenever pregnant woman is exposed • If the pregnant woman is infected,T.pallidum organisms that enter her blood can be transmitted to the fetus
  22. 22. • Transmission to the fetus usually occur between 16-18 weeks of pregnancy(but can happen as early as 9 weeks) • The likehood of transmission is directly related to the stage of syphilis in the infected pregnant woman • The concentration of spirochaettes in blood is highest in the primary and secondary stages of disease and decrease slowly thereafter
  23. 23. Risks associated with syphilis in pregnancy 1. Early fetal death 2. Low birth weight 3. Preterm delivery 4. Neonatal death 5. Infection or disease in newborn
  24. 24. Mother-to-child transmission of syphilis: a continuing public health burden • Nearly 1.5 million pregnant women are infected with syphilis each year • Approximately half of infected pregnant women who are untreated,will experience adverse outcomes due to syphilis • MTCT of syphilis is relatively simple to eliminate,but despite treatments that have been available for over 60 years,MTCT of syphilis persist as major public health problem
  25. 25. • Screening all pregnant women using simple and low cost technologies,and effective treatment with penicillin is feasible even in low resource setting • The exact proportion of pregnant women globally who receive adequate testing and treatment is unknown due to inadequate surveillance
  26. 26. 1. Many of these visits are too late to avert an adverse outcome 2. Clinics may not have offered testing 3. Testing may not have been affordable 4. Women may not have followed up or received their test results 5. Treatment may not have been available 6. Treated women may have been re-infected by untreated sexual partner
  27. 27. Diagnosis and screening • Non-treponemal screening test ,VDRL and RPR test detect antibody to reaginic antigen which found in T.pallidum and some other condition • False positive non-treponemal test result can be associated with various medical conditions unrelated to syphilis,including autoimmune condition,older age and inj drug use • Treponemal test to confirm diagnosis of syphilis should be done
  28. 28. • If a screening test is positive,the serum is then tested by confirmatory treponemal test,using an antigen of T.pallidum,TPHA and TPPA • Treponemal test are more specific than non- treponemal,but they cant differentiate between active untreated syphilis and succcessfuly treated previous infection • Non-treponemal test can distinguish current or recent infection from old or treated infection
  29. 29. Treatment • In early latent stage:single dose of 2.4 million units benzathine penicillin G im • In late latent stage:3 doses of 2.4 million units of benzathine penicillin G im is given once in a week • Erythromycin stearate can be given if there is penicillin hypersensitivity but it crosses placenta poorly
  30. 30. • The newborn baby must therefore be treated with a course of penicillin and consideration given to re-treating the mother • Ceftriaxone 250mg IM for 10 days in many cases
  31. 31. Congenital syphilis Classification • Early congenital syphilis • Late congenital syphilis
  32. 32. Early congenital infection • Defined by clinical manifestations with onset before two years of age • Clinical manifestations in untreated infants usually appear by three month of age,60-90% are asymptomatic at birth • The presence of signs at birth depends upon the timing of intrauterine infection and treatment
  33. 33. Clinical manifestation • Gestational/perinatal:placenta large,thick and pale. Umblical cord inflammed with abscess like foci of necrosis within wharton’s jelly • Systemic :fever,hepatomegaly,generalized lymphadenopathy,failure to thrive ,edema • Mucocutaneous :syphilitic rhinitis,maculopapular rash,vesicular rash,condylomata lata,jaundice
  34. 34. Late congenital syphilis • Defined by clinical manifestations with onset after 2yrs of age • Manifestations are related to scarring or persistent inflammation from early infection and characterized by gumma formation in various tissues • Developed in 40% of untreated syphilis during pregnancy • Some can be prevented by treatment of mother during pregnancy or treatment of infant within 3 month • Some cannot be prevented despite of appropriate treatment
  35. 35. Clinical manifestation Haematologic Musculoskeletal Neurologic Miscellaneous Anaemia (haemolytic in newborn,non haemolytic or chr after 1 month Pseudoparalysis of parrot CSF abnormalities:reacti ve csf vdrl,elevated csf wbc count,elevated csf protein Pneumonia,pneum onitis,respiratory distress Thrombocytopenia( bleeding or petechiae) Radiographic abnormalities:perio statis,wegner sign,wimberger sign Acute syphilitic leptomeningitis Nephrotic syndrome Leukopenia Chronic meningovascular syphilis Leukocytosis
  36. 36. Investigation • RPR/VDRL, TPPA/TPHA (quantitative) • anti-treponemal IgM-EIA, treponemal IgM • Full blood count, liver function, electrolytes. • Cerebrospinal fluid (CSF): cells, protein, RPR/VDRL, TPHA/TPPA • X-rays long bones • Ophthalmic assessment as indicated
  37. 37. Treatment(WHO and CDC recommendations ) Infants with signs of congenital syphilis • Aqueous cristalline benzypenicillin 100000- 150000 units/kg daily for 10 days Infants without signs of congenital syphilis • Benzathine benzylpenicillin G 50000 units/kg im up to adult dose of 2.4 million units in a single dose
  38. 38. Rubella (german measles) • Is the disease caused by the rubella virus,a togavirus • Enveloped ,has a single stranded RNA genome • This virus causes self limited infection in most host • During pregnancy the virus can have potentially devastating effects on developing fetus
  39. 39. • The child may be born with CRS if the mother is infected within the 1st16 weeks of pregnancy • The virus has teratogenic properties • After infecting the placenta ,virus spreads through vascular system of the developing fetus,causing cytopathic damage to blood vessels and ischaemia in the developing organs
  40. 40. • Acquired rubella is transmitted via airborne droplet emission from the upper respiratory tract of active cases and replicates in the nasopharynx and lymph nodes • The virus may also be present in the urine,faeces and on the skin • The disease has an incubation period of 2 to 3 weeks
  41. 41. Clinical features • Rash (erythmatous maculopapular eruption) on the face which spread to the trunk and limbs ,usually fades after 3 days • The facial rash usually clears as it spreads to other part of the body • Low grade fever,joint pains,headache conjuctivitis,sore throat,cough and coryza • Swollen glands(sub occipital and posterior cervical lymphadenopathy)
  42. 42. Congenital rubella syndrome CRS characterized by; Intrauterine growth restriction Intracranial calcifications Microcephaly Cataracts Cardiac defects Neurologic disease Osteitis and hepatosplenomegaly
  43. 43. Vertical transmission and risk of CRS GESTATIONAL AGE RISK OF INFECTION RISK OF CONGENITAL MALFORMATION <11 weeks 80-90% 90% 11-12 weeks 80-90% 33% 13-14 weeks 80-90% 11% 15-16 weeks 60% 25-50% 17-20 weeks 25% negligible 27-30 weeks 35% negligible >36 weeks 100% negligible
  44. 44. Diagnosis Maternal infection • A four fold rise in Rubella IgG antibody titre between acute and convalescent serum specimen • A positive serologic test for rubella specific IgM antibody • A positive rubella culture
  45. 45. Fetal infection • PCR on CVS(chorionic villus sampling) for prenatal diagnosis of intrauterine infection at 10-12 week GA • USS(biometric data)
  46. 46. Management of rubella infection GESTATION AGE STATE OF IMMUNITY MANAGEMENT > 12weeks Known immune No further testing is necessary,CRS has not been reported after maternal infection beyond 12wks <12 weeks Known immune Appropriate counselling should be provided <16weeks Non –immune or immunity unkown Acute and convalescent IgG and IgM should be obtained 16-20 weeks Non –immune or immunity unkown Appropriate counselling,CRS is rare may be manifested by sensorineural deafness >20 weeks Non –immune or immunity unknown Reassured,no studies document CRS after 20wks
  47. 47. Prevention • Active immunisation programs using live,disabled virus vaccines • All girls should be vaccinated against rubella before entering the child bearing years • Women wishing to conceive should be counselled and encouraged to have their antibody status determined and vaccinated if needed
  48. 48. Cytomegalovirus • CMV is a double stranded DNA herpes virus • The CMV seropositivity rate increases with age,geographical location,socioeconomic class and work exposure • CMV infection requires intimate contact through saliva,urine and other body fluids • Possible routes of transmission include sexual contact,organ transplantation,transplacental transmission,transmission via breast milk and blood transfusion
  49. 49. • Primary ,reactivation or recurrent CMV infection can occur in pregnacy and can lead to congenital CMV infection • Transplacental infection can result in IUGR,sensorineural hearing loss,intracalcifications,microcephaly,hydrocephalus,hep atosplenomegaly,delayed psychomotor development,thrombocytopenia and /or optic atrophy • Vertical transmission can occur at any stage of pregnancy,however severe sequelae are more common with infection in the 1st trimester,while the overall risk of infection is greater in the 3rd trimester
  50. 50. • The transmission rate to the fetus is between 30-50% according to the organization of teratology information service • Of those babies who become infected,only 10-15% show signs of congenital CMV after primary maternal infection • Congenital CMV affects about 0.2-2.5% of babies worldwide • Of these only 1-10% of the babies born with the CMV infection will have symptoms at birth and another 10-15% may not show any symptoms at birth,but still may have longterm affects such as hearing loss and learning disability
  51. 51. Diagnosis and management • Serological testing in women with suspected CMV • Amniocentesis • Ultrasonography • Quantitative polymerase chain reaction for viral DNA in amniotic fluid • Iv treatment with CMV hyperimmune globulin • Ganciclovir treatment
  52. 52. Serological test interpretation CMV IgG CMV IgM CMV IgG avidity interpretation Non-reactive Non-rective Not applicable Infection unlikely Reactive Non-reactive High avidity Past infection Reactive Reactive Low avidity Primary infection Reactive Reactive High avidity Non primary infection,low risk for in utero transmission
  53. 53. Herpes Simplex Virus infection • HSV is an ubiquitous enveloped and double stranded DNA virus(family Herpesviridae) • During pregnancy the major concern of maternal HSV infection is transmission to the fetus • HSV-1 predominate orofacial lesion(trigeminal ganglia) • HSV-2 found in the lumbosacral ganglia
  54. 54. Clinical manifestation • Vary depend on the stage of infection and prior immune status • First episode primary infection,describes cases in which HSV is isolated from genital secretions in the absence of HSV antibodies • Present with severe painful genital ulcers,pruritus,dysuria,fever,tender inguinal lymphadenopathy and headache
  55. 55. • First episode non-primary infection,diagnosed when HSV is isolated in woman who have only the other serum HSV-type antibody present • Eg HSV2 isolated from genital secretions in women already expressing serum HSV-1 antibody • Normally genital infection is milder than the primary infection
  56. 56. • Recurrent episodes of HSV infection are characterized by the presence of antibody against the same HSV type and the herpes outbreaks are usually mild (7-10days) with less severe symptoms than the first episode • Preceded by prodromal symptoms such as pruritus,burning or pain before lesion are visible • Mild symptoms and few lesions or no symptoms at all
  57. 57. Vertical transmission • occurs during labor and delivery as a results of direct contact with virus shed from infected sites(cervix,vaginal,perianal area) • Viral shedding can occur in the absence of maternal symptoms and lesions • The frequency of shedding is higher in HSV-2 versus HSV-1 infection
  58. 58. Diagnosis • Presence of vesicular or ulcerated lesion • PCR • Viral culture • Direct fluoroscent antibody test
  59. 59. Management • ACOG recommends that women with active recurrent genital herpes should be offered • Suppressive viral therapy from 36 weeks until delivery valacyclovir 500mg orally bd or Acyclovir 400mg orally tds • C/S is recommended for all women in labour/rupture of membrane with active genital lesions or prodromal symptoms such vulvar pain,burning
  60. 60. • Sitz bath to relieve vulvar pain,fever,dysuria and other local symptoms • Analgesia eg acetaminophen • Avoid transcervical procedure(cerclage,chorionic villus sampling) in women with genital lesions
  61. 61. Prevention • Avoidance of sexual activity during disease • Use of barrier protection • Chronic suppressive therapy to reduce risk of transmission to an uninfected partner • Patient education
  62. 62. References 1. Syphilis during pregnancy,preventable threat to maternal fetal health,Martha W.F,Paula A,Catherine S,december 2016 2. Torch infections,Stagman B,Carey JC 3. Sero-prevalence and factors associated with Toxoplasma gondii infection among pregnant women attending antenatal care in Mwanza,Tz,Berno Mwambe et al 4. Toxoplasmosis and pregnancy,Ruth Gilbert,Vanessa B ,dec 2016,uptodate 5. Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1581–93 6. World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.Pan American Health Organization, March of Dimes, Latin American Centre for Perinatology Women and Reproductive Health. Perinatal infections transmitted by the mother to her infant, education material for health personnel. Clap Scientific Publication. 2008. 7. Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, Broutet N. Global estimates of syphilis in pregnancy and associated adverse outcomes:analysis of multinational antenatal surveillance data. PLoS Med. 2013;10(2):e1001396 8. Centers for Disease Control and Prevention. 2011 Sexually Transmitted Diseases Surveillance- Syphilis. CDC. 2012.World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis. WHO. 2012. 9. Centers for Disease Control and Prevention. Diseases Characterized by Genital, Anal, or Perianal Ulcers - 2010 STD Treatment Guidelines. CDC. 2011.World Health Organization. Sexually transmitted and other reproductive tract infections. WHO. 2005.Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1581–93. 10. Rubella in pregnancy,SOGC clinical practice guidelines,No_203,Feb 2008 11. Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics-normal and problem pregnancies. 4th ed. New York: Churchill Livingstone, Inc.;2002:1328–30 12. A review on TORCH:groups of congenital infection during pregnancy,journal of scientific and innovative research 2014,3(2):258-264 13. Research article on Cytomegalovirus,Parvovirus B19 and Rubella co-infection among pregnant women antending Antenatal clinics in mwanza city,Tanzania:The need to be considered in Tanzania antenatal package ,Mirambo et al 14. Toxoplasmosis during pregnancy:a case report and review of the literature,Giannoulis C et al,2014 15. Seropositivity rate of Rubella and associated factors among pregnant women attending antenatal care in Mwanza ,Tanzania.Mwambe et al,2014 16. Rubella in Pregnancy,SOGC CLINICAL PRACTICE GUIDELINES No.203,Feb 2008 17. Review article on Herpes Simplex Virus Infection in Pregnancy .Gianluca et al ,Feb 2012 18. Seroprevalence and factors associated with Toxoplasma gondii infection among pregnant women attending Antenatal care in the refferal hospital in Tanzania :cross sectional study by Shao ER et al 19. Deborah Watson-Jones, Balthazar Gumodoka, Helen Weiss, John Changalucha, James Todd, Kokungoza Mugeye, Anne Buvé, Zephrine Kanga, Leonard Ndeki, Mary Rusizoka, David Ross, Janeth Marealle, Rebecca Balira, David Mabey, Richard Hayes; Syphilis in Pregnancy in Tanzania. II. The Effectiveness of Antenatal Syphilis Screening and Single-Dose Benzathine Penicillin Treatment for the Prevention of Adverse Pregnancy Outcomes. J Infect Dis 2002; 186 (7): 948-957. doi: 10.1086/342951

Editor's Notes

  • Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur
    Acad Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.
    Pan American Health Organization, March of Dimes, Latin American Centre for Perinatology Women and Reproductive Health. Perinatal infections
    transmitted by the mother to her infant, education material for health personnel. Clap Scientific Publication. 2008.
  • World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.
    Pan American Health Organization, March of Dimes, Latin American Centre for Perinatology Women and Reproductive Health. Perinatal infections
    transmitted by the mother to her infant, education material for health personnel. Clap Scientific Publication. 2008.
  • World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.
  • World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.
  • World Health Organization. The global elimination of congenital syphilis: rationale and strategy for action. WHO. 2007.
  • World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis. WHO. 2012.
  • World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis. WHO. 2012.
  • Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, Broutet N. Global estimates of syphilis in pregnancy and associated adverse outcomes:
    analysis of multinational antenatal surveillance data. PLoS Med. 2013;10(2):e1001396.
  • TABLE 4
    Causes of false-positive serological tests for syphilis
    Nontreponemal testsTreponemal testsAdvancing ageAdvancing ageBacterial endocarditisBrucellosisBrucellosisCirrhosisChancroidDrug addictionChickenpoxGenital herpesDrug addictionHyperglobulinemiaHepatitisImmunizationsIdiopathic thrombocytopenic purpuraInfectious mononucleosisImmunizationsLeptospirosisImmunoglobulin abnormalitiesLeprosyInfectious mononucleosisLyme diseaseIntravenous drug useMalariaLeprosyPintaLymphogranuloma venereumPregnancyMalignancyRelapsing feverMeaslesSclerodermaMumpsSystemic lupus erythematosusPintaThyroiditisPneumococcal pneumoniaYawsPolyarteritis nodosaPregnancyRheumatoid arthritisRheumatic heart diseaseRickettsial diseaseSystemic lupus erythematosusThyroiditisTuberculosisUlcerative colitisVasculitisViral pneumoniaYaws
  • Centers for Disease Control and Prevention. 2011 Sexually Transmitted Diseases Surveillance- Syphilis. CDC. 2012.
    World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis. WHO. 2012.
  • Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur
    Acad Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur
    Acad Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur
    Acad Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur
    Acad Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • Centers for Disease Control and Prevention. Diseases Characterized by Genital, Anal, or Perianal Ulcers - 2010 STD Treatment Guidelines. CDC. 2011.
    World Health Organization. Sexually transmitted and other reproductive tract infections. WHO. 2005.
    Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potočnik M, French P, Patel R. 2014 European guideline on the management of syphilis. J Eur Acad
    Dermatol Venereol. 2014 Dec;28(12):1581–93.
  • Rubella in pregnancy,SOGC clinical practice guidelines,No_203,Feb 2008
  • 7. Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics-normal and problem
    pregnancies. 4th ed. New York: Churchill Livingstone, Inc.;2002:1328–30.
  • Note serologic studies are best performed within 7 to 10 days after the onset of the rash and should be repeated two to three weeks later

×